Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | ING2 | Q9H160 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27724917 | 0.98 | LCK (0.31) | LCKFYNING2 | |
| SCHEMBL6370889 | 0.71 | HDAC6 (0.40) | — | |
| SCHEMBL338619 | 0.71 | CYP2C19 (0.36) | LCKFYNING2 | |
| SCHEMBL10423950 | 0.71 | LCK (0.36) | LCKFYNING2 | |
| SCHEMBL17926194 | 0.67 | ALDH1A1 (0.42) | LCKFYNING2 | |
| Bisdisulizole SCHEMBL7707182 | 0.67 | HDAC6 (0.49) | — | |
| Bisdisulizole SCHEMBL7706777 | 0.67 | HDAC6 (0.49) | — | |
| SCHEMBL5420687 | 0.63 | LCK (0.44) | LCKFYNING2 | |
| SCHEMBL3495112 | 0.63 | ING2 (0.54) | LCKFYNING2 | |
| SCHEMBL3899723 | 0.63 | ALDH1A1 (0.48) | LCKFYNING2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8821842-B2 | Isoalkane mixture, its preparation and use | BASF SE (DE) | 2014-09-02 | — | — | US | disclosed |
| WO-2011107411-A1 | PYRANOPYRANONE DERIVATIVES AS ANTIMICROBIAL AGENTS | BASF SE (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-20090258041-A1 | Protection of Oxidizable Agents | CIBA CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090092642-A1 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure | BEIERSDORF AG (DE) | 2009-04-09 | — | — | US | disclosed |
| CN-101282765-A | Use of polyisobutenyl succinic anhydride-based block copolymers in cosmetic preparations | BASF AG (DE) | 2008-10-08 | — | — | CN | disclosed |
| US-20080193404-A1 | Cosmetic; free from intrinsic odors and have an extremely wide liquid interval; heat transfer liquid; fuel additives and low-temperature fuel; shock absorber oil | BASF AKTIENGESELLSCHAFT (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080182808-A1 | OLIGORIBONUCLEOTIDES FOR THE TREATMENT OF DEGENERATIVE SKIN CONDITIONS BY RNA INTERFERENCE | BEIERSDORF, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20070243147-A1 | Skin and/or Hair Composition Containing Compounds for Increasing The Tanning of Skin | BEIERSDORF AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-7270804-B2 | Use of one or several substances selected from the group of pyrimidines and purines in cosmetic preparations for tanning the skin | BEIERSDORF AG (DE) | 2007-09-18 | — | — | US | disclosed |
| US-20070189984-A1 | Agents for use on skin and/or hair containing quadruply substituted cyclohexene compounds | BEIERSDORF AF, (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070041925-A1 | Skin and hair care preparation containing a combination of protein hydrolyzates | BEIERSDORF AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20060093633-A1 | Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones | BEIERSDORF AG (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20060018869-A1 | Cosmetic or dermatological preparation with a content of creatine, creatinine or derivatives thereof in combination with soybean germ extract | BEIERSDORF AG | 2006-01-26 | — | — | US | disclosed |
| US-20060008440-A1 | Cosmetic or dermatological preparations having a content of anti-freezing proteins and/or anti-freezing glycoproteins | BEIERSDORF AG (DE) | 2006-01-12 | — | — | US | disclosed |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | BEIERSDORF AG | 2005-12-15 | — | — | US | disclosed |
| US-20050261222-A1 | Oligoribonucleotides for the treatment of irritative or inflammatory skin symptoms through RNA interference | BEIERSDORF AG | 2005-11-24 | — | — | US | disclosed |
| US-20050031572-A1 | Cosmetic or dermatological preparations including hops or hop-malt extracts and methods of using same for the prophylaxis and treatment of skin symptoms | BEIERSDORF AG | 2005-02-10 | — | — | US | disclosed |
| US-20050019279-A1 | Cosmetic or dermatological preparation containing an octadecene dioic acid and a UV filtering substance | BEIERSDORF AG | 2005-01-27 | — | — | US | disclosed |
| US-20050002880-A1 | Cosmetic or dermatological preparations containing one or more ketohexoses | BEIERSDORF AG. (DE) | 2005-01-06 | — | — | US | disclosed |
| CN-1535676-A | Face-beautifying/or skin-care composition | 拜埃尔斯多尔夫股份公司 | 2004-10-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070189984-A1 | Agents for use on skin and/or hair containing quadruply substituted cyclohexene compounds | TYR, MC1R, MITF | LCK 2180/4885FYN 3635/4885ING2 2534/4885 |
| US-20050019279-A1 | Cosmetic or dermatological preparation containing an octadecene dioic acid and a UV filtering substance | MC1R, CUTA, DOHH | LCK 3461/4885FYN 3280/4885ING2 4210/4885 |
| US-20050002880-A1 | Cosmetic or dermatological preparations containing one or more ketohexoses | CUTA, TREH, KHK | LCK 1166/4885FYN 2901/4885ING2 4859/4885 |
| US-20080182808-A1 | OLIGORIBONUCLEOTIDES FOR THE TREATMENT OF DEGENERATIVE SKIN CONDITIONS BY RNA INTERFERENCE | DCLRE1B, POLR1C, POLRMT | LCK 2785/4885FYN 3180/4885ING2 2473/4885 |
| US-20080193404-A1 | Cosmetic; free from intrinsic odors and have an extremely wide liquid interval; heat transfer liquid; fuel additives and low-temperature fuel; shock absorber oil | CUTA, TRPA1, FDFT1 | LCK 1270/4885FYN 2192/4885ING2 1146/4885 |
| US-20070243147-A1 | Skin and/or Hair Composition Containing Compounds for Increasing The Tanning of Skin | TYR, MC1R, CUTA | LCK 2378/4885FYN 2825/4885ING2 2525/4885 |
| US-20060008440-A1 | Cosmetic or dermatological preparations having a content of anti-freezing proteins and/or anti-freezing glycoproteins | CUTA, SSB, SERPINA6 | LCK 2736/4885FYN 2508/4885ING2 3976/4885 |
| US-20090258041-A1 | Protection of Oxidizable Agents | LPO, TYR, HAO2 | LCK 4552/4885FYN 4524/4885ING2 1886/4885 |
| US-20060093633-A1 | Cosmetic and/or dermatological preparation comprising 2,3-dibenzylbutyrolactones | DPM1, TYR, DSG1 | LCK 696/4885FYN 1148/4885ING2 3840/4885 |
| US-20050276764-A1 | Topical use of bis-arylimidazo[1,2-a]thiolane derivatives | ITCH, TRPA1, TPH1 | LCK 2189/4885FYN 4510/4885ING2 1851/4885 |
| US-20090092642-A1 | Skin and/or Hair Products, Containing Compounds With an Isoprenoid Structure | SRD5A2, SRD5A1, CUTA | LCK 1558/4885FYN 653/4885ING2 1789/4885 |
| US-20060018869-A1 | Cosmetic or dermatological preparation with a content of creatine, creatinine or derivatives thereof in combination with soybean germ extract | CKMT1A; CKMT1B, AGER, CUTA | LCK 1901/4885FYN 3849/4885ING2 4002/4885 |
| US-20050031572-A1 | Cosmetic or dermatological preparations including hops or hop-malt extracts and methods of using same for the prophylaxis and treatment of skin symptoms | CUTA, TYR, HMBS | LCK 331/4885FYN 857/4885ING2 975/4885 |
| US-20050261222-A1 | Oligoribonucleotides for the treatment of irritative or inflammatory skin symptoms through RNA interference | TLR3, POLR1C, TLR5 | LCK 238/4885FYN 1262/4885ING2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.